Lonza Group Ag ADR LZAGY

$76.56 +0.02 (0.03%)

Valuation

Market cap
53,753,276,000
Revenue TTM
$7,882,920,000
Net income TTM
$-331,930,000
PE ratio
0.00
Forward PE
34.44
Profit margin
-4.21%
Debt to equity
0.51

Trading

Volume
21,700
Avg volume
45,380
Day's range
$76.33 – $76.74
Shares out
702,290,000
Stochastic %K
94%
Beta
1.07
Analysts
Strong Sell
Price target
$79.00

Price

Company profile

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from c...

Show more

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
41 61 316 81 11
Website
https://www.lonza.com
Address
Muenchensteinerstrasse 38, Basel, Switzerland

Latest news

No headlines yet.